	US 12,110,298 B2
	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Mathew M. Mulhern, Lake Villa, IL (US); Fredrik Lars Nordstrom, Ridgefield, CT (US); and Ahmad Y. Sheikh, Lake Forest, IL (US)
Assigned to AbbVie Inc., North Chicago, IL (US)
Filed by AbbVie Inc., North Chicago, IL (US)
Filed on Sep. 18, 2023, as Appl. No. 18/369,272.
Application 18/369,272 is a continuation of application No. 18/137,804, filed on Apr. 21, 2023, abandoned.
Application 18/137,804 is a continuation of application No. 17/902,690, filed on Sep. 2, 2022, abandoned.
Application 17/902,690 is a continuation of application No. 17/184,194, filed on Feb. 24, 2021, abandoned.
Application 17/184,194 is a continuation of application No. 16/656,237, filed on Oct. 17, 2019, abandoned.
Application 16/656,237 is a continuation of application No. 15/891,012, filed on Feb. 7, 2018, abandoned.
Application 15/891,012 is a continuation of application No. 15/295,561, filed on Oct. 17, 2016, abandoned.
Claims priority of provisional application 62/352,380, filed on Jun. 20, 2016.
Claims priority of provisional application 62/301,537, filed on Feb. 29, 2016.
Claims priority of provisional application 62/267,672, filed on Dec. 15, 2015.
Claims priority of provisional application 62/242,797, filed on Oct. 16, 2015.
Prior Publication US 2024/0010656 A1, Jan. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 487/14 (2006.01); A61K 9/00 (2006.01); A61K 31/4985 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/38 (2006.01); C07D 487/04 (2006.01)

CPC C07D 487/14 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4985 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/38 (2013.01); C07D 487/04 (2013.01); C07B 2200/13 (2013.01)]

31 Claims

1. A solid form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) comprising amorphous freebase or Freebase Hydrate Form C.

12. A process for preparing a pharmaceutical tablet, comprising contacting an amorphous freebase solid form of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (Compound 1) with a pharmaceutically acceptable carrier, wherein the amorphous freebase comprises less than about 13% by weight water.